Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Shalom Ben-Shimol; Gili Regev-Yochay; Noga Givon-Lavi; Bart Adriaan Van Der Beek; Tal Brosh-Nissimov; Avi Peretz; Orli Megged; Ron Dagan; Jacob Amir; Galia Barkai; Diana Averbuch; Shraga Aviner; Ahuva Bachinski; Maskit Bar-Meir; Avihu Bar-Yochai; Ilana Benedikt; Rita Bernstein; Tal Brosh-Nissimov; Nael Elias; Dan Engelhard; Moshe Ephros; Daniel Glikman; Giora Gottesman; Galia Grisaru-Soen; Alex Guri; Imad Kasis; Nathan Keller; Zina Korenman; Amir Asher Kuperman; Orli Megged; Dan Miron; Meirav Mor; Hana Ofir-Mintzer; Uri Rubinstein; Yechiel Schlesinger; David Schwartz; Itamar Shalit; Eli Somekh; Isaac Srugo; Alvira Zbriger; Miriam Zucker; Gili Regev-Yochay; Marc Assous; Haim Ben-Zvi; Jihad Bishara; Rita Bardenstein; Larissa Brik; Bibiana Chazan; Michal Chowers; Ronit Cohen-Poradosu; Talia Finn; Alicia Embon; Sarit Freimann; Yuval Geffen; Danny Glikman; Mirit Hershman; Valery Istomin; Michal Katzir; Yoram Kennes; Shirley Khakshoor; Camellia Khoury-Assi; Mandelbaum Sari; Yasmin Maor; Danny Miron; Ilana Oren; Yosi Paitan; Yael Paran; Israel Potasman; Galia Rahav; Hagai Rechnitzer; Klaris Reisenberg; Shifra Sela; David Schwartz; Orna Schwartz; Pninit Shaked-Mishan; Yehudit Sheindler; Gill Smollan; Itzhak Srugo; Michal Stein; Jacob Strahilevitz; Olga Sverdlob; Violetta Temper; Yonit Viener-Well; Gabriel Weber; Miriam Weinberger; Oren Zimchony; Yevgenia Ztibba

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Shalom Ben-Shimol, Gili Regev-Yochay, Noga Givon-Lavi, Bart Adriaan Van Der Beek, Tal Brosh-Nissimov, Avi Peretz, Orli Megged, Ron Dagan, Jacob Amir, Galia Barkai, Diana Averbuch, Shraga Aviner, Ahuva Bachinski, Maskit Bar-Meir, Avihu Bar-Yochai, Ilana Benedikt, Rita Bernstein, Tal Brosh-Nissimov, Nael Elias, Dan EngelhardMoshe Ephros, Daniel Glikman, Giora Gottesman, Galia Grisaru-Soen, Alex Guri, Imad Kasis, Nathan Keller, Zina Korenman, Amir Asher Kuperman, Orli Megged, Dan Miron, Meirav Mor, Hana Ofir-Mintzer, Uri Rubinstein, Yechiel Schlesinger, David Schwartz, Itamar Shalit, Eli Somekh, Isaac Srugo, Alvira Zbriger, Miriam Zucker, Gili Regev-Yochay, Marc Assous, Haim Ben-Zvi, Jihad Bishara, Rita Bardenstein, Larissa Brik, Bibiana Chazan, Michal Chowers, Ronit Cohen-Poradosu, Talia Finn, Alicia Embon, Sarit Freimann, Yuval Geffen, Danny Glikman, Mirit Hershman, Valery Istomin, Michal Katzir, Yoram Kennes, Shirley Khakshoor, Camellia Khoury-Assi, Mandelbaum Sari, Yasmin Maor, Danny Miron, Ilana Oren, Yosi Paitan, Yael Paran, Israel Potasman, Galia Rahav, Hagai Rechnitzer, Klaris Reisenberg, Shifra Sela, David Schwartz, Orna Schwartz, Pninit Shaked-Mishan, Yehudit Sheindler, Gill Smollan, Itzhak Srugo, Michal Stein, Jacob Strahilevitz, Olga Sverdlob, Violetta Temper, Yonit Viener-Well, Gabriel Weber, Miriam Weinberger, Oren Zimchony, Yevgenia Ztibba

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods: A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004-2019 (for adults ≥18 years, 2009-2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake among those >65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004-2008), early-PCV (2009-2011), and late-PCV13 (2016-2019) periods were calculated for different age groups. Results: Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children <5 and 5-17 years, comparing late-PCV13 versus pre-PCV periods (IRR [95% CI]:. 33 [.27-.40] and. 33 [.21-.50], respectively). For adults, comparing late-PCV13 with early-PCV periods, rates significantly declined by 53% in those aged 18-44, while rates did not decline significantly in other age groups. VT13 rates significantly declined in all ages, with decline rates ranging between 94% in children <5 years and 60% in adults ≥85 years. NVT rates significantly increased in <5-, 50-64-, and ≥65-year age groups. In the late-PCV13 period, serotypes 3, 14, and 19A remained the predominant VT13, while serotypes 8 and 12F emerged as predominant NVTs. Conclusions: Continuous monitoring of circulating serotypes in all ages demonstrated direct and indirect PCV effects, which are essential for the development of new vaccination strategies.

Original language	English
Pages (from-to)	1639-1649
Number of pages	11
Journal	Clinical Infectious Diseases
Volume	74
Issue number	9
State	Published - 3 May 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

Keywords

Israel epidemiology
indirect protection
invasive pneumococcal disease
pneumococcal conjugate vaccines

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Cite this

Ben-Shimol, S., Regev-Yochay, G., Givon-Lavi, N., Van Der Beek, B. A., Brosh-Nissimov, T., Peretz, A., Megged, O., Dagan, R., Amir, J., Barkai, G., Averbuch, D., Aviner, S., Bachinski, A., Bar-Meir, M., Bar-Yochai, A., Benedikt, I., Bernstein, R., Brosh-Nissimov, T., Elias, N., ... Ztibba, Y. (2022). Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Clinical Infectious Diseases, 74(9), 1639-1649.

@article{892f9a79a5d94782806a58c4ca0f3254,

title = "Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance",

abstract = "Background: Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods: A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004-2019 (for adults ≥18 years, 2009-2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake among those >65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004-2008), early-PCV (2009-2011), and late-PCV13 (2016-2019) periods were calculated for different age groups. Results: Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children <5 and 5-17 years, comparing late-PCV13 versus pre-PCV periods (IRR [95% CI]:. 33 [.27-.40] and. 33 [.21-.50], respectively). For adults, comparing late-PCV13 with early-PCV periods, rates significantly declined by 53% in those aged 18-44, while rates did not decline significantly in other age groups. VT13 rates significantly declined in all ages, with decline rates ranging between 94% in children <5 years and 60% in adults ≥85 years. NVT rates significantly increased in <5-, 50-64-, and ≥65-year age groups. In the late-PCV13 period, serotypes 3, 14, and 19A remained the predominant VT13, while serotypes 8 and 12F emerged as predominant NVTs. Conclusions: Continuous monitoring of circulating serotypes in all ages demonstrated direct and indirect PCV effects, which are essential for the development of new vaccination strategies.",

keywords = "Israel epidemiology, indirect protection, invasive pneumococcal disease, pneumococcal conjugate vaccines",

author = "Shalom Ben-Shimol and Gili Regev-Yochay and Noga Givon-Lavi and {Van Der Beek}, {Bart Adriaan} and Tal Brosh-Nissimov and Avi Peretz and Orli Megged and Ron Dagan and Jacob Amir and Galia Barkai and Diana Averbuch and Shraga Aviner and Ahuva Bachinski and Maskit Bar-Meir and Avihu Bar-Yochai and Ilana Benedikt and Rita Bernstein and Tal Brosh-Nissimov and Nael Elias and Dan Engelhard and Moshe Ephros and Daniel Glikman and Giora Gottesman and Galia Grisaru-Soen and Alex Guri and Imad Kasis and Nathan Keller and Zina Korenman and {Asher Kuperman}, Amir and Orli Megged and Dan Miron and Meirav Mor and Hana Ofir-Mintzer and Uri Rubinstein and Yechiel Schlesinger and David Schwartz and Itamar Shalit and Eli Somekh and Isaac Srugo and Alvira Zbriger and Miriam Zucker and Gili Regev-Yochay and Marc Assous and Haim Ben-Zvi and Jihad Bishara and Rita Bardenstein and Larissa Brik and Bibiana Chazan and Michal Chowers and Ronit Cohen-Poradosu and Talia Finn and Alicia Embon and Sarit Freimann and Yuval Geffen and Danny Glikman and Mirit Hershman and Valery Istomin and Michal Katzir and Yoram Kennes and Shirley Khakshoor and Camellia Khoury-Assi and Mandelbaum Sari and Yasmin Maor and Danny Miron and Ilana Oren and Yosi Paitan and Yael Paran and Israel Potasman and Galia Rahav and Hagai Rechnitzer and Klaris Reisenberg and Shifra Sela and David Schwartz and Orna Schwartz and Pninit Shaked-Mishan and Yehudit Sheindler and Gill Smollan and Itzhak Srugo and Michal Stein and Jacob Strahilevitz and Olga Sverdlob and Violetta Temper and Yonit Viener-Well and Gabriel Weber and Miriam Weinberger and Oren Zimchony and Yevgenia Ztibba",

year = "2022",

month = may,

day = "3",

language = "English",

volume = "74",

pages = "1639--1649",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

Ben-Shimol, S, Regev-Yochay, G, Givon-Lavi, N, Van Der Beek, BA, Brosh-Nissimov, T, Peretz, A, Megged, O, Dagan, R, Amir, J, Barkai, G, Averbuch, D, Aviner, S, Bachinski, A, Bar-Meir, M, Bar-Yochai, A, Benedikt, I, Bernstein, R, Brosh-Nissimov, T, Elias, N, Engelhard, D, Ephros, M, Glikman, D, Gottesman, G, Grisaru-Soen, G, Guri, A, Kasis, I, Keller, N, Korenman, Z, Asher Kuperman, A, Megged, O, Miron, D, Mor, M, Ofir-Mintzer, H, Rubinstein, U, Schlesinger, Y, Schwartz, D, Shalit, I, Somekh, E, Srugo, I, Zbriger, A, Zucker, M, Regev-Yochay, G, Assous, M, Ben-Zvi, H, Bishara, J, Bardenstein, R, Brik, L, Chazan, B, Chowers, M, Cohen-Poradosu, R, Finn, T, Embon, A, Freimann, S, Geffen, Y, Glikman, D, Hershman, M, Istomin, V, Katzir, M, Kennes, Y, Khakshoor, S, Khoury-Assi, C, Sari, M, Maor, Y, Miron, D, Oren, I, Paitan, Y, Paran, Y, Potasman, I, Rahav, G, Rechnitzer, H, Reisenberg, K, Sela, S, Schwartz, D, Schwartz, O, Shaked-Mishan, P, Sheindler, Y, Smollan, G, Srugo, I, Stein, M, Strahilevitz, J, Sverdlob, O, Temper, V, Viener-Well, Y, Weber, G, Weinberger, M, Zimchony, O & Ztibba, Y 2022, 'Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance', Clinical Infectious Diseases, vol. 74, no. 9, pp. 1639-1649.

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. / Ben-Shimol, Shalom; Regev-Yochay, Gili; Givon-Lavi, Noga et al.
In: Clinical Infectious Diseases, Vol. 74, No. 9, 03.05.2022, p. 1639-1649.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era

T2 - A Nationwide Prospective Surveillance

AU - Ben-Shimol, Shalom

AU - Regev-Yochay, Gili

AU - Givon-Lavi, Noga

AU - Van Der Beek, Bart Adriaan

AU - Brosh-Nissimov, Tal

AU - Peretz, Avi

AU - Megged, Orli

AU - Dagan, Ron

AU - Amir, Jacob

AU - Barkai, Galia

AU - Averbuch, Diana

AU - Aviner, Shraga

AU - Bachinski, Ahuva

AU - Bar-Meir, Maskit

AU - Bar-Yochai, Avihu

AU - Benedikt, Ilana

AU - Bernstein, Rita

AU - Brosh-Nissimov, Tal

AU - Elias, Nael

AU - Engelhard, Dan

AU - Ephros, Moshe

AU - Glikman, Daniel

AU - Gottesman, Giora

AU - Grisaru-Soen, Galia

AU - Guri, Alex

AU - Kasis, Imad

AU - Keller, Nathan

AU - Korenman, Zina

AU - Asher Kuperman, Amir

AU - Megged, Orli

AU - Miron, Dan

AU - Mor, Meirav

AU - Ofir-Mintzer, Hana

AU - Rubinstein, Uri

AU - Schlesinger, Yechiel

AU - Schwartz, David

AU - Shalit, Itamar

AU - Somekh, Eli

AU - Srugo, Isaac

AU - Zbriger, Alvira

AU - Zucker, Miriam

AU - Regev-Yochay, Gili

AU - Assous, Marc

AU - Ben-Zvi, Haim

AU - Bishara, Jihad

AU - Bardenstein, Rita

AU - Brik, Larissa

AU - Chazan, Bibiana

AU - Chowers, Michal

AU - Cohen-Poradosu, Ronit

AU - Finn, Talia

AU - Embon, Alicia

AU - Freimann, Sarit

AU - Geffen, Yuval

AU - Glikman, Danny

AU - Hershman, Mirit

AU - Istomin, Valery

AU - Katzir, Michal

AU - Kennes, Yoram

AU - Khakshoor, Shirley

AU - Khoury-Assi, Camellia

AU - Sari, Mandelbaum

AU - Maor, Yasmin

AU - Miron, Danny

AU - Oren, Ilana

AU - Paitan, Yosi

AU - Paran, Yael

AU - Potasman, Israel

AU - Rahav, Galia

AU - Rechnitzer, Hagai

AU - Reisenberg, Klaris

AU - Sela, Shifra

AU - Schwartz, David

AU - Schwartz, Orna

AU - Shaked-Mishan, Pninit

AU - Sheindler, Yehudit

AU - Smollan, Gill

AU - Srugo, Itzhak

AU - Stein, Michal

AU - Strahilevitz, Jacob

AU - Sverdlob, Olga

AU - Temper, Violetta

AU - Viener-Well, Yonit

AU - Weber, Gabriel

AU - Weinberger, Miriam

AU - Zimchony, Oren

AU - Ztibba, Yevgenia

PY - 2022/5/3

Y1 - 2022/5/3

N2 - Background: Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods: A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004-2019 (for adults ≥18 years, 2009-2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake among those >65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004-2008), early-PCV (2009-2011), and late-PCV13 (2016-2019) periods were calculated for different age groups. Results: Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children <5 and 5-17 years, comparing late-PCV13 versus pre-PCV periods (IRR [95% CI]:. 33 [.27-.40] and. 33 [.21-.50], respectively). For adults, comparing late-PCV13 with early-PCV periods, rates significantly declined by 53% in those aged 18-44, while rates did not decline significantly in other age groups. VT13 rates significantly declined in all ages, with decline rates ranging between 94% in children <5 years and 60% in adults ≥85 years. NVT rates significantly increased in <5-, 50-64-, and ≥65-year age groups. In the late-PCV13 period, serotypes 3, 14, and 19A remained the predominant VT13, while serotypes 8 and 12F emerged as predominant NVTs. Conclusions: Continuous monitoring of circulating serotypes in all ages demonstrated direct and indirect PCV effects, which are essential for the development of new vaccination strategies.

AB - Background: Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods: A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004-2019 (for adults ≥18 years, 2009-2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine (PPV-23) uptake among those >65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004-2008), early-PCV (2009-2011), and late-PCV13 (2016-2019) periods were calculated for different age groups. Results: Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children <5 and 5-17 years, comparing late-PCV13 versus pre-PCV periods (IRR [95% CI]:. 33 [.27-.40] and. 33 [.21-.50], respectively). For adults, comparing late-PCV13 with early-PCV periods, rates significantly declined by 53% in those aged 18-44, while rates did not decline significantly in other age groups. VT13 rates significantly declined in all ages, with decline rates ranging between 94% in children <5 years and 60% in adults ≥85 years. NVT rates significantly increased in <5-, 50-64-, and ≥65-year age groups. In the late-PCV13 period, serotypes 3, 14, and 19A remained the predominant VT13, while serotypes 8 and 12F emerged as predominant NVTs. Conclusions: Continuous monitoring of circulating serotypes in all ages demonstrated direct and indirect PCV effects, which are essential for the development of new vaccination strategies.

KW - Israel epidemiology

KW - indirect protection

KW - invasive pneumococcal disease

KW - pneumococcal conjugate vaccines

UR - http://www.scopus.com/inward/record.url?scp=85129997719&partnerID=8YFLogxK

M3 - Article

C2 - 34293091

AN - SCOPUS:85129997719

SN - 1058-4838

VL - 74

SP - 1639

EP - 1649

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this